Article Figures & Data
Figures
- FIGURE 1.
Example of ROI definition for meningioma (left), HGG (center), and nontumor (right).
- FIGURE 2.
Example of ROI definition in several slices of PET scan of meningioma patient.
- FIGURE 3.
Example of μi estimated in different slices in case of meningioma (left) and glioma (right).
- FIGURE 4.
Photograph of probe prototype.
- FIGURE 5.
Measured SUV (left) and TNR (right) on all studied meningioma lesions. Lesions from same patient share same symbols. ID = sequential number identifying a lesion.
- FIGURE 6.
Measured SUV (left) and TNR (right) on all studied HGG lesions. ID = sequential number identifying a lesion.
Tables
Patient no. Nles. Weight (kg) Aadm (MBq) ν*† (Hz) νNT*† (Hz) 
*† (s)* (MBq/kg)Diagnosis Previous treatment M01 1 63 220 32.2 1.9 0.2 0.7 Atypical S M02 1 80 160 17.6 2.6 0.6 1.9 Atypical S/RT/PRRT M03 3 95 305 33.7 3.5 0.3 0.9 Likely atypical S/RT 50.3 3.5 0.3 0.5 76.8 3.5 0.1 0.3 M04 1 48 200 89.4 4.5 0.1 0.2 Atypical S/RT/CT M05 3 57 130 66.7 4.4 0.2 0.3 Relapse S/RT/CT/PRRT 53.2 4.4 0.2 0.5 57.6 4.4 0.2 0.4 M06 2 90 145 107.6 1.8 0.1 0.1 Unknown PRRT 56.1 1.8 0.2 0.4 M07 1 74 237 50.2 3.9 0.2 0.5 Anaplastic S/RT M08 3 105 223 55.7 3.6 0.2 0.5 Atypical S/RT 31.2 3.6 0.2 0.9 29.6 3.6 0.4 0.9 M09 2 48 145 13.4 2.4 0.9 2.7 Atypical S/RT 15.1 2.4 0.7 2.5 M10 1 70 240 14.6 1.2 0.6 1.8 Atypical S/RT 12.6 1.2 0.8 1.9 M11 1 75 220 12.7 3.8 1.6 5.0 Atypical Unknown ↵* Data assume 12 h between administration of 90Y and surgery.
↵† Estimations assume that reference activity Aref = 3 MBq/kg is administered.
Nles. = number of lesions; Aadm = administered activity; ν = signal rate expected on probe in each lesion; νNT = nontumor rate expected on probe in each lesion;
= time needed to identify a 0.1-mL residual; = the minimum activity that needs to be administered to have ; S = surgery; RT = radiotherapy; PRRT = peptide receptor radionuclide therapy; CT = chemotherapy.
Patient no. Weight (kg) Aadm (MBq) ν*† (Hz) νNT*† (Hz) *† (s)* (MBq/kg)Diagnosis Previous treatment G01 97 246 16.5 1.4 0.5 1.5 HGG S/RT/CT/PRRT G02 68 223 5.2 1.1 2.6 8.5 HGG RT/CT/B G03 80 152 9.6 1.9 1.4 4.3 HGG S/RT/CT G04 93 198 22.4 3.7 0.6 1.8 HGG S/RT/CT/PRRT G05 90 192 4.6 2.0 7.4 23.6 HGG S/RT/CT/PRRT G06 60 185 4.4 1.6 5.8 20.0 HGG S/RT/CT G07 63 194 4.8 1.7 5.1 17.6 HGG S/RT/CT G08 70 266 2.1 0.8 — 40.0 HGG RT/CT G09 85 255 3.7 1.1 5.3 17.6 HGG S/RT/CT G10 80 224 2.2 1.6 — — Oligodendroglioma S/RT/CT/I G11 70 234 5.1 2.0 5.5 18.8 HGG RT/CT G12 15 38 5.0 2.0 5.9 18.8 Pontine glioma RT/CT/PRRT ↵* Data assume 12 h between administration of 90Y and surgery.
↵† Estimations assume that reference activity Aref = 3 MBq/kg is administered.
Nles. = number of lesions; Aadm = administered activity; ν = signal rate expected on probe in each lesion; νNT = nontumor rate expected on probe in each lesion;
= time needed to identify a 0.1-mL residual; = the minimum activity that needs to be administered to have ; S = surgery; RT = radiotherapy; CT = chemotherapy; PRRT = peptide receptor radionuclide therapy; B = bevacizumab; I = immunotherapy.
Jump to section
Related Articles
Cited By...
- The Complementary Role of 68Ga-DOTATATE PET/CT in Diagnosis of Recurrent Meningioma
- Improved Detection of Transosseous Meningiomas Using 68Ga-DOTATATE PET/CT Compared with Contrast-Enhanced MRI
- Non-routine Tracers for PET Imaging of High-grade Glioma
- Time Evolution of DOTATOC Uptake in Neuroendocrine Tumors in View of a Possible Application of Radioguided Surgery with {beta}- Decay